Generic placeholder image

Current Psychopharmacology

Editor-in-Chief

ISSN (Print): 2211-5560
ISSN (Online): 2211-5579

Research Article

A Pilot Study of Plasma Antipsychotic Drugs Concentrations of First Episode Patients with Psychosis From Epirus - Greece

Author(s): Vassiliki A. Boumba*, Petros Petrikis, Lisbeth Patteet, Maria Baou , Georgios Rallis, Apostolos Metsios, Andreas Karampas, Kristof Maudens and Venetsanos Mavreas

Volume 8 , Issue 2 , 2019

Page: [123 - 129] Pages: 7

DOI: 10.2174/1573412914666180611110805

Abstract

Background: This contribution is a study on plasma antipsychotics concentrations of first episode outpatients with psychosis (FEPs), under antipsychotic treatment; it aims to attract attention to the importance of the drug-driven management of psychiatric patients for improving adherence and clinical efficacy.

Methods: The plasma antipsychotic concentrations were determined retrospectively (after the completion of selection of all samples) and therefore, they were not used to monitor patients’ response to pharmacotherapy. A total of 120 plasma samples from 35 psychiatric patients were collected and tested for antipsychotics. The concentrations of eight antipsychotic drugs (amisulpride, aripiprazole, clozapine, haloperidol, olanzapine, quetiapine, risperidone and paliperidone) and seven of their metabolites were determined.

Results: Overall, 74% of the samples had therapeutic antipsychotic levels, 19% had subtherapeutic concentrations, while supra-therapeutic concentrations were measured for clozapine (7%). Therapeutic drug concentrations were recorded in 54% of plasma samples from patients being under olanzapine medication and in all patients under long-acting injectables. Sub-therapeutic levels were either attributed to non-adherence, or they reflected residual levels due to medication changes. Supra-therapeutic levels were recorded for clozapine and were not followed by adverse effects.

Conclusion: This is the first study on antipsychotic plasma levels conducted in Greece. Our results show the importance of performing measurement of plasma antipsychotics levels, at appropriate time intervals, for improving adherence, clinical decision making and thus clinical efficacy. Especially for FEPs, such approach could contribute to early detection of treatment limitations and improve outcome.

Keywords: Antipsychotics, quantification, plasma, first-episode patients, long-acting injectable, adherence, drug analysis, therapeutic drug monitoring.

Graphical Abstract
[1]
Hiemke C, Baumann P, Bergemann N, et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update. Pharmacopsychiatry 2011; 44: 195-235.
[2]
Young SL, Taylor M, Lawrie SM. “First do not harm.” A systematic review of the prevalence and management of antipsychotic adverse effects. J Psychopharmacol 2015; 29: 353-62.
[3]
Werner FM, Coveñas R. Safety of antipsychotic drugs: focus on therapeutic and adverse effects. Expert Opin Drug Saf 2014; 13: 1031-42.
[4]
Kaufmann A, Wartelsteiner F, Yalcin-Siedentopf N, et al. Changes in psychopathology in schizophrenia patients starting treatment with new-generation antipsychotics: therapeutic drug monitoring in a naturalistic treatment setting. Eur Neuropsychopharmacol 2016; 26: 717-28.
[5]
Velligan DI, Weiden PJ, Sajatovi M, et al. The expert Consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry 2009; 70: 1-46.
[6]
Boumba VA, Georgiadis M, Mirescu N, Vougiouklakis T. Fatal intoxications in a forensic autopsy material from Epirus, Greece, during the period 1998-2010. J Forensic Sci 2013; 58: 425-31.
[7]
Emsley R, Chiliza B, Asmal L. The evidence of illness progression after relapse in schizophrenia. Schizophr Res 2013; 148: 117-21.
[8]
Patteet L, Maudens KE, Sabbe B, Morrens M, De Doncker M, Neels H. High throughput identification and quantification of 16 antipsychotics and 8 major metabolites in serum using ultra-high performance liquid chromatography-tandem mass spectrometry. Clin Chim Acta 2014; 429: 51-8.
[9]
Boumba VA, Rallis G, Petrikis P, Vougiouklakis T, Mavreas V. Determination of clozapine, and five antidepressants in human plasma, serum and whole blood by gas chromatography-mass spectrometry: a simple tool for clinical and postmortem toxicological analysis. J Chrom B 2016; 1038: 43-8.
[10]
Baselt RC. Disposition of toxic drugs and chemicals in man10th ed Biomedical Publications: Seal Beach. 2014.
[11]
Schulz M, Iwersen-Bergmann S, Andresen H, Schmoldt A. Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics. Crit Care 2012; 16(4): R136.
[12]
Rabinovitch M, Béchard-Evans L, Schmitz N, Joober R, Malla A. Early predictors of nonadherence to antipsychotic therapy in first-episode psychosis. Can J Psychiatry 2009; 54: 28-35.
[13]
Baldeli S, Clementi E, Cattaneo D. Can we rely on AGNP therapeutic targets also for LAI antipsychotics? Pharmacopsychiatry 2017; 51(06): 270-1.
[14]
Kane JM, Kishimoto T, Correll CU. Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry 2013; 12: 216-26.
[15]
Patteet L, Maudens KE, Vermeulen Z, et al. Retrospective evaluation of therapeutic drug monitoring of clozapine and norclozapine in Belgium using a multidrug UHPLC-MS/MS method. Clin Biochem 2014; 47: 336-9.
[16]
Yalcin-Siedentopf N, Wartelsteiner F, Kaufmann A, et al. Measuring adherence to medication in schizophrenia: the relationship between attitudes toward drug therapy and plasma levels of new-generation antipsychotics. Int J Neuropsychopharmacol 2015; 18: 1-7.
[17]
Paz E, Bouzas L, Hermida J, Brenlla J, Tutor JC. Evaluation of three dosing models for the prediction of steady-state trough clozapine concentrations. Clin Biochem 2008; 41: 603-6.
[18]
Patel MX, Bowskill S, Couchman L. Plasma olanzapine in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1999-2009. J Clin Psychopharmacol 2011; 31: 411-7.

© 2022 Bentham Science Publishers | Privacy Policy